Administration of STING-activating nanoparticles strongly remodels the tumor immune microenvironment, induces potent limitation of tumor growth, prolongs the overall survival, and improves the response of immune checkpoint inhibitors [212, 213]. The gene discussed is STING1; the disease is neoplasm.